$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

$fhtx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021022556 Filed on November 09, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q2
Revenue	$713.0K	$41.00K	$279.0K
YoY Change	185.2%	-77.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.332M	$5.808M	$4.898M
YoY Change	38.86%	126.88%	156.44%
% of Gross Profit
Research & Development	$22.46M	$20.49M	$18.64M
YoY Change	36.39%	27.19%	36.79%
% of Gross Profit
Depreciation & Amortization	$810.0K	$800.0K	$800.0K
YoY Change	42.11%	166.67%	300.0%
% of Gross Profit
Operating Expenses	$28.80M	$26.30M	$23.54M
YoY Change	36.92%	40.89%	51.49%
Operating Profit		-$26.26M	-$23.26M
YoY Change		42.04%	49.69%
Interest Expense	-$426.0K	$499.0K	$495.0K
YoY Change	33.13%	147.03%	150.0%
% of Operating Profit
Other Income/Expense, Net	$598.0K	$181.0K	$150.0K
YoY Change	6.79%	48.36%	-181.52%
Pretax Income	-$29.14M	-$26.08M	-$23.11M
YoY Change	40.38%	41.97%	47.02%
Income Tax
% Of Pretax Income
Net Earnings	-$29.14M	-$26.08M	-$23.11M
YoY Change	40.38%	41.99%	46.99%
Net Earnings / Revenue	-4087.38%	-63609.76%	-8283.51%
Basic Earnings Per Share		-$0.71	-$0.63
Diluted Earnings Per Share	-$766.0K	-$0.71	-$0.63
COMMON SHARES
Basic Shares Outstanding	37.09M shares	36.97M shares	36.85M shares
Diluted Shares Outstanding		36.97M shares	36.85M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$154.3M	$120.8M	$141.3M
YoY Change	-16.95%	61.99%	285.99%
Cash & Equivalents	$101.1M	$57.84M	$125.2M
Short-Term Investments	$53.15M	$63.00M	$16.11M
Other Short-Term Assets	$5.273M	$3.111M	$3.399M
YoY Change	7.61%	0.35%	41.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$459.6M	$124.0M	$144.7M
YoY Change	141.0%	59.4%	270.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.08M	$57.95M	$59.68M
YoY Change	187.17%	243.97%	11.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.400M	$2.431M	$2.445M
YoY Change	185.04%	1052.13%	35.83%
Total Long-Term Assets	$60.21M	$62.12M	$63.85M
YoY Change	-7.23%	-3.94%	15.47%
TOTAL ASSETS
Total Short-Term Assets	$459.6M	$124.0M	$144.7M
Total Long-Term Assets	$60.21M	$62.12M	$63.85M
Total Assets	$519.8M	$186.1M	$208.5M
YoY Change	103.36%	30.64%	121.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.819M	$3.821M	$3.406M
YoY Change	3.78%	7.51%	13.53%
Accrued Expenses	$9.562M	$14.09M	$5.152M
YoY Change	4.38%	41.31%	-31.31%
Deferred Revenue	$28.32M	$1.278M	$910.0K
YoY Change	1299.06%	-24.65%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$106.0K
YoY Change			-97.88%
Total Short-Term Liabilities	$48.69M	$19.30M	$16.41M
YoY Change	158.37%	-9.41%	3.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$20.00M	$20.00M
YoY Change	-100.0%	127.25%	94.17%
Other Long-Term Liabilities	$143.0K	$171.0K	$67.90M
YoY Change		-99.75%	35.52%
Total Long-Term Liabilities	$143.0K	$20.17M	$20.00M
YoY Change	-99.27%	129.19%	-66.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.69M	$19.30M	$16.41M
Total Long-Term Liabilities	$143.0K	$20.17M	$20.00M
Total Liabilities	$422.9M	$105.1M	$104.3M
YoY Change	286.54%	5.78%	36.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$264.3M	-$235.1M	-$209.0M
YoY Change	62.18%	65.36%
Common Stock	$4.000K	$4.000K	$4.000K
YoY Change	0.0%	300.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$96.87M	$80.98M	$104.2M
YoY Change
Total Liabilities & Shareholders Equity	$519.8M	$186.1M	$208.5M
YoY Change	103.36%	30.64%	121.13%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$29.14M	-$26.08M	-$23.11M
YoY Change	40.38%	41.99%	46.99%
Depreciation, Depletion And Amortization	$810.0K	$800.0K	$800.0K
YoY Change	42.11%	166.67%	300.0%
Cash From Operating Activities	$11.88M	-$20.50M	-$18.48M
YoY Change	-211.46%	-850.99%	46.67%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	-$230.0K	-$1.213M
YoY Change	-98.93%	-95.76%	-46.09%
Acquisitions
YoY Change
Other Investing Activities	$9.753M	-$47.10M	$78.30M
YoY Change	-110.52%
Cash From Investing Activities	$9.673M	-$47.33M	$77.09M
YoY Change	-109.65%	773.21%	-3526.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	21.74M	505.0K	113.0K
YoY Change	-83.08%	-98.76%	-99.76%
NET CHANGE
Cash From Operating Activities	11.88M	-20.50M	-18.48M
Cash From Investing Activities	9.673M	-47.33M	77.09M
Cash From Financing Activities	21.74M	505.0K	113.0K
Net Change In Cash	43.29M	-67.32M	58.72M
YoY Change	145.58%	-276.89%	77.35%
FREE CASH FLOW
Cash From Operating Activities	$11.88M	-$20.50M	-$18.48M
Capital Expenditures	-$80.00K	-$230.0K	-$1.213M
Free Cash Flow	$11.96M	-$20.27M	-$17.27M
YoY Change	-477.35%	-348.74%	66.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Entity Central Index Key EntityCentralIndexKey	0001822462
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39634
	dei	Entity Registrant Name EntityRegistrantName	Foghorn Therapeutics Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5271393
	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Technology Square, Ste 700
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	586-3100
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	FHTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37091588	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57841000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92795000	USD
CY2021Q3	us-gaap	Marketable Securities MarketableSecurities	63001000	USD
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	92975000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3111000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4917000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	123953000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	190687000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39606000	USD
CY2021Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	18346000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	19528000	USD
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1733000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1733000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2431000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	842000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42804000	USD
CY2021Q3	us-gaap	Assets Assets	186069000	USD
CY2020Q4	us-gaap	Assets Assets	255594000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3821000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3680000	USD
CY2021Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7206000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9161000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6991000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3981000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1278000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2024000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	19296000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18846000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	19914000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	19654000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53020000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	58361000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12686000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12546000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	171000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2021Q3	us-gaap	Liabilities Liabilities	105087000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	109407000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37044763	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37044763	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36790946	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36790946	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	316104000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	309126000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-235113000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162936000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	80982000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	146187000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186069000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	255594000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	179000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	606000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	179000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20494000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16113000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57862000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41244000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5808000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2555000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15396000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6687000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	26302000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	18668000	USD
	us-gaap	Operating Expenses OperatingExpenses	73258000	USD
	us-gaap	Operating Expenses OperatingExpenses	47931000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-26261000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18489000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72652000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-47752000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	499000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	202000	USD
	us-gaap	Interest Expense InterestExpense	1480000	USD
	us-gaap	Interest Expense InterestExpense	658000	USD
CY2021Q3	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	680000	USD
CY2020Q3	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	394000	USD
	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	1955000	USD
	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	437000	USD
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2020Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	70000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	69000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	181000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	122000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.96
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	475000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-290000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-26080000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-18367000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72177000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48042000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.96
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.76
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.76
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36971767	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36971767	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5884027	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5884027	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36879392	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36879392	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5487154	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5487154	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-26080000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-18367000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72177000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48042000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2042000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26083000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18367000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72183000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48042000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	146187000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1888000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	13000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22986000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	125164000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	111000	USD
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-16000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-23111000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	104190000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	505000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2370000	USD
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-26080000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	80982000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-88016000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	247000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	517000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-13952000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-101204000	USD
CY2020Q2	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	489000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-15723000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-116411000	USD
CY2020Q3	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	578000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	877000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-18367000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-133323000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72177000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48042000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	6300000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1883000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2417000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	764000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	69000	USD
	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	3198000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3233000	USD
	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	3103000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	260000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	179000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-82000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-316000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1725000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	156000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-374000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	253000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-198000	USD
	fhtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2331000	USD
	fhtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	8889000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-606000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	14821000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62132000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20631000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8694000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	89737000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	119470000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26500000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8694000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	89861000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	678000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	852000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	500000	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	1249000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	678000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	88964000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34954000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	59639000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94528000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17255000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59574000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76894000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1218000	USD
	us-gaap	Interest Paid Net InterestPaidNet	490000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6602000	USD
	fhtx	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	0	USD
	fhtx	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	721000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57841000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74620000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	1733000	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	2274000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	63014000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59574000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76894000	USD
CY2020Q3	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-235100000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	63001000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	92982000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	92975000	USD
CY2021Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	22866000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	21631000	USD
CY2021Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	4520000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	2103000	USD
CY2021Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	18346000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	19528000	USD
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	800000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	800000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3242000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3513000	USD
CY2021Q3	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	3067000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2020Q4	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	2146000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	780000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	979000	USD
CY2021Q3	fhtx	Accrued Tenant Improvements AccruedTenantImprovements	9000	USD
CY2020Q4	fhtx	Accrued Tenant Improvements AccruedTenantImprovements	2385000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	108000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	138000	USD
CY2021Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7206000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9161000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6248423	shares
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	833000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	10000000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	9167000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20000000	USD
CY2021Q3	fhtx	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27120934	shares
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2367000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	877000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6297000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1883000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	23200000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000	USD
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15000000	USD
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	14000000	USD
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1887000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2162000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	5660000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	5145000	USD
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2020Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	46000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	731000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	225000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	2222000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	617000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	2618000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	2387000	USD
	us-gaap	Lease Cost LeaseCost	7882000	USD
	us-gaap	Lease Cost LeaseCost	5808000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6991000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	7219000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	1571000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	38306000	USD
	fhtx	Change In Operating Lease Liability Right Of Use Asset Remeasurement ChangeInOperatingLeaseLiabilityRightOfUseAssetRemeasurement	0	USD
	fhtx	Change In Operating Lease Liability Right Of Use Asset Remeasurement ChangeInOperatingLeaseLiabilityRightOfUseAssetRemeasurement	7384000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y10M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0535
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0535
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2468000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9957000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10051000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10377000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10626000	USD
CY2021Q3	fhtx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	30584000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	74063000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12598000	USD
CY2021Q3	fhtx	Lessee Operating Lease Liability Estimated Lease Incentives LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives	1454000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	60011000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53020000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	60011000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2400000	USD
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	700000	USD
CY2020Q3	us-gaap	Sublease Income SubleaseIncome	300000	USD
	us-gaap	Sublease Income SubleaseIncome	1900000	USD
	us-gaap	Sublease Income SubleaseIncome	300000	USD

Files In Submission

Name	View Source	Status
0001628280-21-022556-index-headers.html	Edgar Link	pending
0001628280-21-022556-index.html	Edgar Link	pending
0001628280-21-022556.txt	Edgar Link	pending
0001628280-21-022556-xbrl.zip	Edgar Link	pending
fhtx-20210930.htm	Edgar Link	pending
fhtx-20210930.xsd	Edgar Link	pending
fhtx-20210930xex311.htm	Edgar Link	pending
fhtx-20210930xex312.htm	Edgar Link	pending
fhtx-20210930xex321.htm	Edgar Link	pending
fhtx-20210930xex322.htm	Edgar Link	pending
fhtx-20210930_cal.xml	Edgar Link	unprocessable
fhtx-20210930_def.xml	Edgar Link	unprocessable
fhtx-20210930_htm.xml	Edgar Link	completed
fhtx-20210930_lab.xml	Edgar Link	unprocessable
fhtx-20210930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

2021 Q4 Form 10-Q Financial Statement

#000162828021022556 Filed on November 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX Foghorn Therapeutics Inc. Stock $fhtx

2021 Q4 Form 10-Q Financial Statement

#000162828021022556 Filed on November 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx